RaQualia Pharma Inc. (4579.T)
- Previous Close
554.00 - Open
553.00 - Bid 546.00 x --
- Ask 547.00 x --
- Day's Range
545.00 - 554.00 - 52 Week Range
527.00 - 943.00 - Volume
12,400 - Avg. Volume
115,081 - Market Cap (intraday)
11.793B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-11.97 - Earnings Date Aug 8, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 3 clinical trial in the United States; and grapiprant for cancer, which is in phase I clinical trial in China and the United States, as well as grapiprant for pain management The company also provides veterinary products, such as grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the indication of chronic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial; Cyclooxygenase-2 inhibitor, which is in phase I clinical trials for the indication of pain; CB2 agonist for pain; selective sodium channel blocker for pain and itch; P2X7 receptor antagonist, which is in Phase 2 clinical trials for the target indication of chronic pain. It has a collaborative agreement with Socium Corporation and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.
www.raqualia.co.jpRecent News: 4579.T
Performance Overview: 4579.T
Trailing total returns as of 5/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4579.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4579.T
Valuation Measures
Market Cap
11.99B
Enterprise Value
12.86B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.39
Price/Book (mrq)
1.96
Enterprise Value/Revenue
5.79
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-11.61%
Return on Assets (ttm)
-1.30%
Return on Equity (ttm)
-4.13%
Revenue (ttm)
2.18B
Net Income Avi to Common (ttm)
-253M
Diluted EPS (ttm)
-11.97
Balance Sheet and Cash Flow
Total Cash (mrq)
3.18B
Total Debt/Equity (mrq)
67.52%
Levered Free Cash Flow (ttm)
-901.37M